News

Enlarge image

BusinessHungaryPoland

Hungary and Poland join forces

24.05.2013 - Hungary and Poland will cooperate to create a biotech cluster with global reach.

On the first day of the Bioforum conference in Budapest, the heads of the Polish and Hungarian biotech associations signed a cooperation agreement aimed at creating a joint cluster. „Hungary and Poland separately are not able to build an effective and strong business cluster for the biotech sector,“ said Erno Duda, President of the Hungarian Biotech Association (HBA). „After having signed this cooperation agreement we have a great chance to create such a cluster, which will develop in scale of international biotech market and, at the same time, will support local initiative and start-ups.“ Tadeusz Pietrucha, who heads the recently launched Polish Biotech Association (PBA) added: „The global biotech market is hard to reach for small and medium companies from the CEE region. Therefore, we have to cooperate to show our potential in…the biotech world”.

The agreement summarises the most pressing needs of the life sciences sector in both nations but also in the whole Central and Eastern Europe (CCE) region. Both associations will join their forces and their member companies’ skills to attract more national funding and EU grants as well as international collaborators from the biotech and pharmaceutical sector. The plan is supported by their national governments, represented by Grazyna Henclewska, undersecretary of Polish Ministry of Economy and by Zoltán Cséfalvay, vice-minister of Hungarian National Economy, at the  conference.

Biotechnology plays an increasing role in the CEE countries. While the sector is young, it is growing and has a strong science base, with biosimilar drug developers, clinical and contract research organisations, and life sciences research companies. Most recently, IBM signed an agreement with Poland’s new Centre for Pre-clinical Research and Technology (CePT), a €100m EU investment aimed at pooling researcher know-how from three universities and seven research institutes to create a fully integrated drug discovery and diagnostics value chain.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/hungary-and-poland-join-forces.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.50 EUR12.78%
  • BIOCARTIS GROUP NV (B)7.57 EUR7.53%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%

FLOP

  • NICOX (F)11.57 EUR-8.61%
  • KAROLINSKA (S)7.55 SEK-4.43%
  • AB SCIENCE (F)14.20 EUR-4.05%

TOP

  • PROTHENA PLC (IE)53.17 USD49.9%
  • FLAMEL TECHNOLOGIES (F)12.49 USD32.2%
  • TIGENIX (B)1.05 EUR26.5%

FLOP

  • MOLOGEN (D)1.50 EUR-40.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SANTHERA (CH)56.75 CHF-18.9%

TOP

  • KARO BIO (S)28.70 SEK1705.0%
  • NICOX (F)11.57 EUR493.3%
  • SAREUM HOLDINGS (UK)0.64 GBP166.7%

FLOP

  • BB BIOTECH (D)45.22 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.64 SEK-79.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 24.07.2016